NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease

Clinical Nephrology

Volumn 71, Issue 4, 2009, Pages 380-386

  Svensson, M ^a   Gorst Rasmussen, A ^b   Schmidt, E B ^b   Jorgensen, K A ^b   Christensen, J H ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiovascular disease; End stage renal disease; Heart failure; Natriuretic peptides; Prognostic marker

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CHOLESTEROL; FIBRINOGEN; HEMOGLOBIN; TROPONIN T;

AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 66649103645     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71380     Document Type: Article

References (24)

1. Alehagen U, Lindstedt G, Eriksson H, Dahlstrom U. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem. 2003; 49: 1337-1346.
2. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL Jr. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006; 47: 91-97.
3. Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi - biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin Tand I in end-stage renal disease for all-cause death. Clin Chem. 2004; 50: 2279-2285.
4. Berdague P, Caffin PY, Barazer I, Vergnes C, Sedighian S, Letrillard S, Pilossof R, Goutorbe F, Piot C, Reny JL. Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. Am Heart J. 2006; 151: 690-698.
5. Clerico A, Caprioli R, Del RS, Giannessi D. Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest. 2001; 24: 24-30.
6. deWinter RJ, Stroobants A, Koch KT, Bax M, Schotborgh CE, Mulder KJ, Sanders GT, van Straalen JP, Fischer J, Tijssen JG, Piek JJ. Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention. Am J Cardiol. 2004; 94: 1481-1485.
7. DeFilippi CR, Fink JC, Nass CM, Chen H, Christenson R. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis. 2005; 46: 35-44.
8. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995; 47: 186-192.
9. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995; 47: 884-890.
10. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004; 110: 3206-3212.
11. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005; 95: 948-954.
12. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005; 352: 666-675.
13. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 2007; 71: 548-554.
14. McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC Jr. Aminoterminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 2006; 47: 874-880.
15. McMurray JJ. Chronic kidney disease in patients with cardiac disease: a review of evidence-based treatment. Kidney Int. 2005; 68: 1419-1426.
16. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996; 11: 1277-1285.
17. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. 2007; 50: 1009-1019.
18. Schou M, Dalsgaard MK, Clemmesen O, Dawson EA, Yoshiga CC, Nielsen HB, Gustafsson F, Hildebrandt PR, Secher NH. Kidneys extract BNP and NT-proBNP in healthy young men. J Appl Physiol. 2005; 99: 1676-1680.
19. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, Collinson PO, Brecker SJ. Raised plasma N-terminal pro-B-type natriuretic peptide concentrations predict mortality and cardiac disease in end stage renal disease. Heart. 2006; 92: 1518-1519.
20. Sommerer C, Beimler J, Schwenger V, Heckele N, Katus HA, Giannitsis E, Zeier M. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest. 2007; 37: 350-356.
21. Svensson M, Schmidt EB, Jorgensen KA, Christensen JH. n-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol. 2006; 1: 780-786.
22. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355: 1126-1130.
23. Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem. 2004; 50: 1071-1074.
24. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-pro BNP in clinical routine. Heart. 2006; 92: 843-849.